US Market Report for Crohn's Disease Immunology Drugs 2018 - MedCore

Thursday, November 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, Nov. 15, 2017 /PRNewswire/ --

General Report Contents- Market Analyses include: Unit Sales, ASPs,

Market Value & Growth Trends

Download the full report: https://www.reportbuyer.com/product/5175234

- Market Drivers & Limiters for each chapter segment- Competitive Analysis for each chapter segment- Section on recent mergers

& acquisitions

Endoscopy procedures and biopsy are commonly used in the diagnosis of Crohn's disease as well as medical imaging and description of the disease and symptoms. There are no medications or surgery that can cure Crohn's disease. The treatment directs to minimize the effect of symptoms, maintain remission and prevent deterioration in the patient's condition.

Treatment options include medication to control the symptoms, lifestyle and dietary changes, reduction of stress, moderate activity and exercise. Acute treatment involves antibiotics, anti-inflammatory drugs and corticosteroids. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Most of these therapies (aminosalicylates, steroids and immunomodulators) provide symptomatic improvement but fail to change the disease course.Aminosalicylates are often more effective in ulcerative colitis. This treatment showed positive results in mild to moderate UC. Aminosalicylates may be helpful to control mild inflammation and symptoms of CD. Monotherapy is an option to induce remission in people with a first presentation or a single inflammatory exacerbation of CD. It is usually offered with a conventional glucocorticosteroid (prednisolone, methylprednisolone or intravenous hydrocortisone).

AbstractCrohn's disease (CD) is a type of an inflammatory bowel disease or IBD. CD is an inflammation that may affect any part of the gastrointestinal (GI) tract. It is a chronic condition that can occur for any reason, at any age and the condition is equally prevalent in both males and females.

Crohn's disease and an ulcerative colitis (UC) affect the GI system with similar symptoms while the course of the diseases and treatments may be different. Both diseases refer to a group of chronic disorders that causes inflammation or ulceration in a gastrointestinal tract, called an inflammatory bowel disease. UC usually affects the large intestine (rectum and colon), while CD can affect any part of the GI tract.

Scope2014-2024

Download the full report: https://www.reportbuyer.com/product/5175234

About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers.

For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

 

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-crohns-disease-immunology-drugs-2018---medcore-300557093.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store